225 related articles for article (PubMed ID: 28243127)
1. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.
Lan X; Li S; Gao H; Nanding A; Quan L; Yang C; Ding S; Xue Y
Onco Targets Ther; 2017; 10():919-926. PubMed ID: 28243127
[TBL] [Abstract][Full Text] [Related]
2. Role of BTLA/HVEM network in development of gastric cancer.
Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
[TBL] [Abstract][Full Text] [Related]
3. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
4. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
Demerlé C; Gorvel L; Olive D
Front Oncol; 2021; 11():682007. PubMed ID: 34532285
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
7. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
9. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Vendel AC; Jaroszewski L; Linnik MD; Godzik A
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38676311
[TBL] [Abstract][Full Text] [Related]
10. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
[TBL] [Abstract][Full Text] [Related]
11. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
13. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.
Aubert N; Brunel S; Olive D; Marodon G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208480
[TBL] [Abstract][Full Text] [Related]
14. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N; Macagno N; Granjeaud S; Granier C; Moutardier V; Gaudy-Marqueste C; Habel N; Mandavit M; Guillot B; Pasero C; Tartour E; Ballotti R; Grob JJ; Olive D
Oncoimmunology; 2019; 8(12):e1665976. PubMed ID: 31741766
[TBL] [Abstract][Full Text] [Related]
15. Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2.
Cheng TY; Liu YJ; Yan H; Xi YB; Duan LQ; Wang Y; Zhang TT; Gu YM; Wang XD; Wu CX; Gao S
Cells; 2022 Dec; 11(24):. PubMed ID: 36552785
[TBL] [Abstract][Full Text] [Related]
16. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
17. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator.
Nelson CA; Fremont MD; Sedy JR; Norris PS; Ware CF; Murphy KM; Fremont DH
J Immunol; 2008 Jan; 180(2):940-7. PubMed ID: 18178834
[TBL] [Abstract][Full Text] [Related]
19. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
20. The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
Hu X
Breast Cancer; 2024 May; 31(3):358-370. PubMed ID: 38483699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]